日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Long-term follow-up demonstrates the curative potential of dual CD19/CD22 CAR-T-cell therapy alone or combined with autologous stem cell transplantation in TP53-altered relapsed/refractory B-cell non-Hodgkin lymphoma

长期随访结果表明,对于TP53改变的复发/难治性B细胞非霍奇金淋巴瘤,单独使用或联合自体干细胞移植的双重CD19/CD22 CAR-T细胞疗法具有治愈潜力。

Mao, Zekai; Peng, Juan; Cao, Yang; Wang, Na; Wang, Jue; Yang, Yang; Xu, Jinghuan; Meng, Fankai; Chen, Liting; Mao, Xia; Guo, Jiaqi; Zhou, Xiaoxi; Zhang, Yicheng; Wei, Jia

CD19 CAR-T cells for treatment-refractory autoimmune diseases: the phase 1/2 CASTLE basket trial

CD19 CAR-T 细胞治疗难治性自身免疫性疾病:CASTLE 篮子试验(1/2 期)

Müller, Fabian; Hagen, Melanie; Wirsching, Andreas; Kharboutli, Soraya; Aigner, Michael; Völkl, Simon; Kretschmann, Sascha; Tascilar, Koray; Taubmann, Jule; Bucci, Laura; Raimondo, Maria Gabriella; Bergmann, Christina; Rothe, Tobias; Corte, Giulia; Tur, Carlo; Muñoz, Luis; Böltz, Sebastian; Schuster, Louis; Hartmann, Fabian; Garantziotis, Panagiotis; Spörl, Silvia; Vasova, Ingrid; Gerbitz, Armin; Spriewald, Bernd; Kiener, Hans; Giannarelli, Diana; Locatelli, Franco; D'Agostino, Maria-Antonietta; Hanssens, Linda; Miltenyi, Stefan; Bozec, Aline; Grieshaber-Bouyer, Ricardo; Mackensen, Andreas; Schett, Georg

Patterns, risk factors and management of CD19-directed chimeric antigen receptor T-cell therapy failure in CNS lymphoma

CD19靶向嵌合抗原受体T细胞疗法治疗中枢神经系统淋巴瘤失败的模式、危险因素及管理

Kaulen, Leon D; Karschnia, Philipp; Doubrovinskaia, Sofia; Abramson, Jeremy S; Soumerai, Jacob D; Martinez-Lage, Maria; Haydu, J Erika; Shankar, Ganesh M; Patel, Chirayu; Choi, Bryan D; Barnes, Jeffrey A; El-Jawahri, Areej; Hochberg, Ephraim P; Johnson, P Connor; Wick, Wolfgang; Maus, Marcela V; Chen, Yi-Bin; Frigault, Matthew J; Dietrich, Jorg

BCMA-CD19 armored compound CAR T cells in systemic lupus erythematosus: extended follow-up of a phase 1 clinical trial

BCMA-CD19 修饰的 CAR-T 细胞治疗系统性红斑狼疮:一项 1 期临床试验的长期随访

Hong, Ming; Wang, Mingxia; Zeng, Ronghao; Ding, Ling; He, Shanzhi; Lan, Ting; DeStefano, Vincent M; Wada, Masayuki; Pinz, Kevin; Chow, Jennifer E; Choi, Byeong Hyeok; Hagag, Nabil; Wang, Min; Ma, Yu; Luo, Jing; Liang, Yingwen; Ding, Shihao; Lu, Ziji; Zhang, Wenli; Ma, Yupo; Wang, Weijia

Vascular inflammation in patients undergoing anti-CD19 chimeric antigen receptor-T cells for haematologic malignancies: a call for cardiovascular surveillance

接受抗CD19嵌合抗原受体T细胞治疗血液系统恶性肿瘤患者的血管炎症:呼吁进行心血管监测

Camilli, Massimiliano; Guarneri, Andrea; Leccisotti, Lucia; Ballacci, Federico; Viscovo, Marcello; Galli, Eugenio; Maggio, Luca; Tinti, Lorenzo; Lamendola, Priscilla; Hohaus, Stefan; Sica, Simona; Sorà, Federica; Chiusolo, Patrizia; Lanza, Gaetano Antonio; Liuzzo, Giovanna; Burzotta, Francesco; Giordano, Alessandro; Crea, Filippo; Lombardo, Antonella; Minotti, Giorgio

De novo CD19- B-ALL: awareness of a rare entity in initial diagnosis

新发 CD19- B 细胞急性淋巴细胞白血病:初诊时需重视这种罕见疾病

Hagos, Tsigab; Zhao, Chen

Author Correction: Whole-body CD8(+) T-cell PET imaging in patients with large B-cell lymphoma before and during CD19-directed CAR T-cell therapy: a phase 2 study

作者更正:CD19靶向CAR T细胞疗法治疗前后大B细胞淋巴瘤患者的全身CD8(+) T细胞PET成像:一项II期研究

de Boer, Janneke W; Keijzer, Kylie; van Doesum, Jaap A; Smit, Nienke A M; Brouwers, Adrienne H; van Sluis, Joyce; Lub-de Hooge, Marjolijn N; Pierik, Frank R; Huls, Gerwin A; van Dijk, Lisanne V; Visser, Lydia; Diepstra, Arjan; Noordzij, Walter; Williams, Simon P; Ungewickell, Alexander; Elias, Sjoerd G; de Vries, Elisabeth G E; Niezink, Anne G H; van Meerten, Tom

Tumor-associated CD19(+) macrophages induce immunosuppressive microenvironment in hepatocellular carcinoma

肿瘤相关CD19(+)巨噬细胞在肝细胞癌中诱导免疫抑制性微环境

Wang, Junli; Cao, Wanyue; Huang, Jinyan; Zhou, Yu; Zheng, Rujia; Lou, Yu; Yang, Jiaqi; Yan, Jiawei; Tang, Jianghui; Ye, Mao; Hong, Zhengtao; Wu, Jiangchao; Ding, Haonan; Zhang, Yuquan; Sheng, Jianpeng; Lu, Xinjiang; Xu, Pinglong; Lu, Xiongbin; Bai, Xueli; Liang, Tingbo; Zhang, Qi

Immunometabolic determinants of long-term response in leukemia patients receiving CD19 CAR T cell therapy.

接受 CD19 CAR T 细胞治疗的白血病患者长期疗效的免疫代谢决定因素。

Goldberg Lior, Haas Eric R, Wu Jiaqi, Garcia Bryan, Urak Ryan, Vyas Vibhuti, Espinosa Ruby, Munoz Tamara, Bierkatz Shirley, Pathak Khyatiben V, Hansen Nathaniel P, Pirrotte Patrick, Singhal Jyotsana, Figarola James L, Noriega Ricardo Zerda, Li Zhuo, Wi Dasol, Tanaka Erin, Geltink Ramon Klein, Chen Min-Hsuan, Wu Xiwei, Wagner Jamie R, Paul Jinny, Clark Mary C, Ngo Dat, Aldoss Ibrahim, Forman Stephen J, Wang Xiuli

Correction to "Outcomes of patients with relapsed or refractory primary mediastinal B-cell lymphoma treated with anti-CD19 CAR-T cells: CARTHYM, a study from the French national DESCAR-T registry"

对“接受抗CD19 CAR-T细胞治疗的复发或难治性原发性纵隔B细胞淋巴瘤患者的疗效:CARTHYM,一项来自法国国家DESCAR-T注册中心的研究”的更正